Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-43.18%
0%
-43.18%
6 Months
-12.28%
0%
-12.28%
1 Year
-53.7%
0%
-53.7%
2 Years
-80.0%
0%
-80.0%
3 Years
-85.71%
0%
-85.71%
4 Years
-95.69%
0%
-95.69%
5 Years
-81.75%
0%
-81.75%
Sareum Holdings Plc for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-1.02%
EBIT Growth (5y)
-201.94%
EBIT to Interest (avg)
-2.94
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.96
Sales to Capital Employed (avg)
0.03
Tax Ratio
22.55%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
8.02
EV to EBIT
-8.97
EV to EBITDA
-8.97
EV to Capital Employed
30.56
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-340.60%
ROE (Latest)
-47.85%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
Bullish
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
No Trend
No Trend
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Annual Results Snapshot (Consolidated) - Jun'23
Jun'23
Jun'22
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-4.00
-2.60
-53.85%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-3.20
-2.20
-45.45%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
Net Sales
YoY Growth in year ended Jun 2023 is 0.00% vs 0.00% in Jun 2022
Consolidated Net Profit
YoY Growth in year ended Jun 2023 is -45.45% vs -46.67% in Jun 2022
About Sareum Holdings Plc 
Sareum Holdings Plc
Miscellaneous
Sareum Holdings plc is engaged in the discovery and development of new therapeutic drugs by a combination of skills in biology, computational chemistry and medicinal chemistry. The Company's drug programs include Checkpoint Kinase 1 (CHK1), Aurora+FLT3 Kinase and Tyrosine Kinase 2- autoimmune diseases (TYK2), Aurora+FLT3 kinase and TYK2 kinase-cancer. Its Chk1 program is the advanced program and shows potency in disease models of lung and colon cancers in combination with chemotherapy; acute myeloid leukemia (AML) and B-cell lymphoma, and head and neck cancers in combination with radiotherapy. TYK2 kinase program focuses on developing a series of TYK2 inhibitors that can be dosed orally against various autoimmune and inflammatory disorders, including psoriasis and rheumatoid arthritis. Its Aurora+FLT3 Kinase program focuses on AML and other blood cancers. Its TYK2 kinase prevents T-cell acute lymphoblastic leukemia (T-ALL) cells from proliferating by causing programmed cell death.
Company Coordinates 
Company Details
Unit 2A, Langford Arch, London Road, Pampisford CAMBRIDGE None : CB22 3FX
Registrar Details






